Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVIg plus prednisone versus prednisone plus placebo in newly diagnosed myositis
NL-OMON60781Phase 2Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Oct 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Autoimmune Myopathies comparing IVIg + prednisone with Placebo + prednisone (2 arms). Primary endpoint: Treatment response at 12 weeks. Started Oct 2024; status: completed.
02
Drugs
subcuviaprednisone
03
Conditions
Autoimmune Myopathies
Beyond the preview
Go deeper on NL-OMON60781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60781.